Article
Immunology
Jerald Sadoff, Els De Paepe, Wouter Haazen, Edmund Omoruyi, Arangassery R. Bastian, Christy Comeaux, Esther Heijnen, Cynthia Strout, Hanneke Schuitemaker, Benoit Callendret
Summary: The study showed that coadministration of Ad26.RSV.preF and seasonal influenza vaccine in older adults is safe and effective, without interfering with immune response.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Virology
Pramila Lamichhane, Megan E. Schmidt, Megolhubino Terhuja, Steven M. Varga, Timothy A. Snider, Christina A. Rostad, Antonius G. P. Oomens
Summary: This study used a trans-complementing approach to develop live attenuated RSV vaccines, with the membrane-anchored preF vaccine showing protective effects in mice, indicating its potential for being an effective and safe vaccine.
Review
Microbiology
Wanderson Rezende, Hadley E. Neal, Rebecca E. Dutch, Pedro A. Piedra
Summary: Respiratory syncytial virus (RSV) is a major cause of hospitalizations and deaths in young children and older adults. The development of an RSV vaccine, primarily targeting the fusion (F) protein, has become a global priority. However, there are still unanswered questions about the mechanism of RSV entry and the process of RSV F triggering and fusion promotion. This review focuses on these questions, particularly the cleaved peptide p27 within the F protein.
FRONTIERS IN MICROBIOLOGY
(2023)
Article
Pharmacology & Pharmacy
Su-Hwa Lee, Ki-Back Chu, Min-Ju Kim, Jie Mao, Gi-Deok Eom, Keon-Woong Yoon, Md Atique Ahmed, Fu-Shi Quan
Summary: Respiratory syncytial virus (RSV) causes severe respiratory disease and there is currently no effective treatment or vaccine available. In this study, virus-like particle (VLP) vaccines expressing RSV proteins were produced and evaluated in mice. The VLPs induced a strong antibody response and neutralizing activity, with the Pre-F+G VLPs showing superior protection. VLP immunization also reduced viral titer and inflammation in the lungs of mice. These results suggest that Pre-F+G VLPs could be a potential vaccine candidate against RSV infection.
Article
Immunology
Arabella S. Stuart, Miia Virta, Kristi Williams, Ilkka Seppa, Robyn Hartvickson, Melanie Greenland, Edmund Omoruyi, Arangassery Rosemary Bastian, Wouter Haazen, Nadine Salisch, Efi Gymnopoulou, Benoit Callendret, Saul N. Faust, Matthew D. Snape, Esther Heijnen
Summary: A randomized, double-blind study in adults and children showed that a novel Ad26 vector-based RSV vaccine encoding preF-protein given as two doses demonstrated acceptable safety and tolerability up to 1 year, with evidence of humoral and cellular immunogenicity.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Immunology
James Baber, Mark Arya, Yuben Moodley, Anna Jaques, Qin Jiang, Kena A. Swanson, David Cooper, Mohan S. Maddur, Jakob Loschko, Alejandra Gurtman, Kathrin U. Jansen, William C. Gruber, Philip R. Dormitzer, Beate Schmoele-Thoma
Summary: The stabilized RSV prefusion F subunit (RSVpreF) vaccine candidate was well tolerated and elicited strong and persistent serum neutralizing responses in adults aged 65-85, with or without adjuvant. Adjuvanted formulations did not show additional enhancement of immune responses.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Virology
Pramila Lamichhane, Megolhubino Terhuja, Timothy A. Snider, Antonius G. P. Oomens
Summary: The study utilized a novel vaccine to enhance the induction of anti-G antibodies against RSV, resulting in improved protection in mice experiments.
Article
Immunology
Li Ma, Matthew Brecher, Allison Soufal, Tiziano Gaiotto, Sai Tian, Sumana Chandramouli, Vincent Dewar, Laurent Ferrant, Meng Zhang, Xianzhi Zhou, Varnika Roy
Summary: In the past decade, camelid nanobodies have been developed for various applications, but their potential in evaluating vaccine antigen candidates has been relatively unexplored. This study demonstrates the suitability of a nanobody-based ELISA method for characterizing a leading respiratory syncytial virus (RSV) vaccine candidate. The nanobody, F-VHH-L66, exhibits similar characteristics to the well-known antibody AM14 in recognizing the prefusion form of RSV F, which is crucial for generating neutralizing antibodies. The F-VHH-L66-based ELISA proves to be specific, accurate, linear, and stability-indicating, making it a potential alternative to AM14 for RSVPreF3 characterization.
Article
Biotechnology & Applied Microbiology
Antonios O. Aliprantis, Christine A. Shaw, Paul Griffin, Nicholas Farinola, Radha A. Railkar, Xin Cao, Wen Liu, Jeffrey R. Sachs, Christine J. Swenson, Heather Lee, Kara S. Cox, Daniel S. Spellman, Colleen J. Winstead, Igor Smolenov, Eseng Lai, Tal Zaks, Amy S. Espeseth, Lori Panther
Summary: This study evaluated the safety, tolerability, and immunogenicity of a new RSV vaccine in healthy younger and older adults. All doses of the vaccine were well tolerated and induced both humoral and cell-mediated immune responses.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2021)
Article
Immunology
Jiachen Huang, Rose J. J. Miller, Jarrod J. J. Mousa
Summary: Respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) are major causes of severe respiratory infections. A chimeric fusion protein containing immunodominant epitopes of both RSV F and hMPV F has been shown to generate neutralizing antibodies and provide protection against both viruses.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Javier Diez-Domingo, Xavier Saez-Llorens, Miguel A. Rodriguez-Weber, Cristina Epalza, Archana Chatterjee, Cheng-Hsun Chiu, Chien-Yu Lin, Andrea A. Berry, Federico Martinon-Torres, Fernando Baquero-Artigao, Joanne M. Langley, Jose T. Ramos Amador, Joseph B. Domachowske, Li-Min Huang, Nan-Chang Chiu, Susanna Esposito, Philippe Moris, Thi Lien-Anh Nguyen, Vanja Nikic, Wayne Woo, Yingjun Zhou, Ilse Dieussaert, Amanda Leach, Antonio Gonzalez Lopez, Nicolas Vanhoutte
Summary: This study tested a new candidate RSV vaccine in toddlers who had a previous RSV infection. The vaccine was effective in preventing RSV-related illnesses and triggered an antibody response that could neutralize the virus. No vaccine-related serious adverse events or RSV-related hospitalizations were reported during the study.
JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Immunology
Vadim Ivanov, Antonius G. P. Oomens, James F. Papin, Rachel Staats, Darlene N. Reuter, Zhongxin Yu, Pedro A. Piedra, Robert C. Wellliver
Summary: RSV is a major viral respiratory pathogen for infants and children, with no licensed vaccine available. A vaccine has been developed using a human RSV strain with the M protein gene deleted, preventing viral replication. Vaccination led to reduced illness signs and viral replication in infected animals, supporting further development for human use.
Article
Immunology
C. Garrett Rappazzo, Ching-Lin Hsieh, Scott A. Rush, Emma S. Esterman, Teresa Delgado, James C. Geoghegan, Anna Z. Wec, Mrunal Sakharkar, Vicente Mas, Jason S. McLellan, Laura M. Walker
Summary: In this study, the B cell responses to hMPV were investigated using high-throughput single-cell technology, and rare and highly potent broadly neutralizing antibodies targeting specific epitopes were identified. Additionally, monotherapy with neutralizing antibodies targeting different antigenic sites showed effective protection against lower respiratory tract infection. This study provides promising monoclonal antibody candidates for passive immunoprophylaxis and informs the design of hMPV vaccines.
Article
Immunology
Tino F. Schwarz, Casey Johnson, Christine Grigat, Dan Apter, Peter Csonka, Niklas Lindblad, Thi Lien-Anh Nguyen, Feng F. Gao, Hui Qian, Antonella N. Tullio, Ilse Dieussaert, Marta Picciolato, Ouzama Henry
Summary: This first-in-human, placebo-controlled study showed that the unadjuvanted RSVPreF3 vaccine, at doses of 30, 60, or 120 μg, was well tolerated and immunogenic. Dose levels of 60 and 120 μg exhibited significantly higher immunogenicity compared to the 30 μg dose, leading to further investigation in pregnant women.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Virology
Yu Zhao, Chen Ma, Jie Yang, Xiufen Zou, Zishu Pan
Summary: UV-RSV vaccination induces a Th2 type inflammatory response in the lungs, characterized by enhanced histopathology, reduced Treg cells, and increased IL4(+)CD4 T cells. Additionally, UV-RSV vaccination leads to increased production of several Th2 type cytokines and decreases in IL-6 and IL-17.